Wilson Sonsini Goodrich & Rosati has advised Azalea Therapeutics on the transaction. Azalea Therapeutics, a biotechnology company specializing in precision genomic medicines delivered in vivo, has...
Azalea Therapeutics Secures $82 Million in Seed and Series A Financing for In Vivo Genomic Medicine Platform
GSK Acquires Worldwide License for Empirico’s COPD Candidate EMP-012
Wilson Sonsini Goodrich & Rosati has advised Empirico, and Davis Polk & Wardwell has advised GSK. GSK plc and Empirico Inc. have entered into a worldwide...
Absci’s Collaboration with Astrazeneca
Wilson Sonsini Goodrich & Rosati advised Absci on the transaction. Absci Corporation (Nasdaq: ABSI) announced a collaboration with AstraZeneca, a global biopharmaceutical company, to deliver an AI-designed...
Switch’s $52 Million Financing
Wilson Sonsini Goodrich & Rosati advised Switch Therapeutics on the transaction and launch. Switch Therapeutics, a preclinical stage biotechnology company pioneering a new way to use...
Insilico Medicine’s Research Collaboration with Sanofi
Wilson Sonsini Goodrich & Rosati advised Insilico Medicine on the transaction. Insilico Medicine, a clinical-stage artificial intelligence-driven drug discovery company, announced a multi-year, multi-target strategic research...
Synthekine’s Collaboration and License Agreement with Merck
Wilson Sonsini Goodrich & Rosati advised Synthekine on the deal. Synthekine Inc., an engineered cytokine therapeutics company, announced that it has entered into a worldwide research...